Does the HMG-CoA reductase inhibitor pravastatin influence nucleation of cholesterol crystals in supersaturated model bile?

European Journal of Gastroenterology and Hepatology

Volumn 8, Issue 3, 1996, Pages 197-200

  Smit, Jan W A ^a,b   Van Erpecum, Karel J ^a   Gadella, Mirielle M ^a   Van De Heyning, Bert J M ^a   Van Berge Henegouwen, Gerard P ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bile; Cholesterol crystals; HMG CoA reductase inhibitors; Nucleation; Pravastatin

Indexed keywords

CHOLAGOGUE; CHOLESTEROL; ENZYME INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; PRAVASTATIN; TAURODEOXYCHOLIC ACID;

ARTICLE; BILE; CHEMISTRY; CHOLELITHIASIS; CRYSTALLIZATION; DRUG EFFECT; DRUG INTERACTION; HUMAN; PHASE CONTRAST MICROSCOPY; TIME; CONTROLLED STUDY; CRYSTAL; GALLSTONE FORMATION; PRIORITY JOURNAL;

ANTICHOLESTEREMIC AGENTS; BILE; CHOLAGOGUES AND CHOLERETICS; CHOLELITHIASIS; CHOLESTEROL; CRYSTALLIZATION; DRUG INTERACTIONS; ENZYME INHIBITORS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MICROSCOPY, PHASE-CONTRAST; PRAVASTATIN; TAURODEOXYCHOLIC ACID; TIME FACTORS;

EID: 0029666089     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-199603000-00002     Document Type: Article

References (27)

1. Duane WC, Hunninghake DB, Freeman ML, Pooler PA, Schlasner L, Gebhard RL: Simvastatin, a competitive inhibitor of HMG-CoA reductase lowers cholesterol saturation index of gallbladder bile. Hepatology 1988, 8:1147-1150.
2. Hoogerbrugge-vd Linden N, de Rooy FWM, Jansen H, van Blankenstein M: Effect of pravastatin on biliary lipid composition and bile synthesis in familial hypercholesterolaemia. Gut 1990, 31:348-350.
3. Tazuma S, Hatsushika S, Aihara N, Sagawa H, Yamashita G, Sasaki M, et al.: Inhibitory effects of pravastatin, a competitive inhibitor of hydroxymethylglutaryl coenzyme A reductase, on cholesterol gallstone formation in prairie dogs. Digestion 1992, 51:179-184.
4. Saunders KD, Cates JA, Abedin MZ, Rege SR, Festekdjian SF, Howard W, et al.: Lovastatin inhibits gallstone formation in the cholesterol fed prairie dog. Ann Surg 1991, 214:149-153.
5. Smit JWA, Van Erpecum KJ, Renooij W, Stolk MFJ, Edgar P, Doornewaard H et al.: The effects of the HMG-CoA reductase inhibitor pravastatin on bile composition and nucleation of cholesterol crystals in cholesterol gallstone disease. Hepatology 1995, 21:1523-1529.
6. Bazzoli F, Mazella G, Zagari RM et al.: HMG-CoA reductase inhibitors lower biliary cholesterol saturation but are ineffective cholesterol gallstone dissolving agents [Abstract]. Gastroenterology 1992, 102:A302.
7. Vickers S, Duncan CA, Vyas KP, et al.: In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase. Drug Metab Dispos 1990, 18:476-483.
8. Scott WA: Hydrophilicity and the differential pharmacology of pravastatin. Lipid Management. Round Table Series 1990, No.16: 17-25.
9. Singhvi SM, Pan HY, Morrison RA: Disposition of pravastatin sodium, a tissue selective HMG-CoA-reductase inhibitor in healthy subjects. Br J Clin Pharmacol 1990, 29:239-243.
10. Scott WA, Mahoney EM, Mosley ST. Mechanism of action and differential pharmacology of pravastatin, a hydrophilic and selective HMG-CoA-reductase inhibitor. In New Advances in the Control of Lipid Metabolism: Focus on Pravastatin. Edited by JC LaRosa. London: Royal Society of Medicine Services International Congress and Symposium Series no 162; 1989:1-8.
11. Everett DW, Chando TJ, Didonato GC, Singhvi SM, Pan HY, Weinstein SH: Biotransformation of pravastatin sodium in humans. Drug Metab Disp 1991, 19:740-748.
12. Pentikainen PJ, Saraheimo M, Schwartz JI, et al.: Comparative pharmacokinetics of lovastatin, simvastatin and pravastatin in humans. J Clin Pharmacol 1992, 32:136-140.
13. Koga T, Shimada Y, Kuroda M, et al.: Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Biochim Biophys Acta 1990, 1045:115-120.
14. Kibe A, Dudley MA, Halpern Z, Lynn MP, Breuer AC, Holzbach RT: Factors affecting cholesterol monohydrate crystal nucleation time in model systems of supersaturated bile. J Lipid Res 1985, 26:1102-1111.
15. Carey MC: Critical tables for calculating the cholesterol saturation of native bile. J Lipid Res 1978, 19:945-955.
16. Groen AK, Ottenhof R, Jansen PLM, van Marie J, Tytgat GNJ: Effect of cholesterol nucleation-promoting activity on cholesterol stabilisation in model bile. J Lipid Res 1989, 30:51-58.
17. Allain CC, Poon LS, Chan CSG, Richmond W, Fu PC: Enzymatic determination of total serum cholesterol. J Clin Chem 1974, 20:470-475.
18. Gurantz D, Laker MF, Hofmann AF: Enzymatic measurement of choline containing phospholipids in bile. J Lipid Res 1981, 22:373-376.
19. Turley SD, Dietschy JM: Reevaluation of the 3-hydroxysteroid dehydrogenase assay for total bile acids in bile. J Lipid Res 1978, 19:924-928.
20. Holan KR, Holzbach HR, Hermann RE, Cooperman AM, Claffey WJ: Nucleation time: a key factor in the pathogenesis of cholesterol gallstone disease. Gastroenterology 1979, 77:611-617.
21. Van Erpecum KJ, Van Berge-Henegouwen GP, Stoelwinder B, Stolk MFJ, Eggink WF, Govaert WHA: Cholesterol and pigment gallstone disease: comparison of three bile tests for differentiation between the two stone types. Scand J Gastroenterol 1988, 23:948-954.
22. Reihner E, Rudling M, Stahlberg D, et al.: Influence of pravastatin, a specific inhibitor of HMG-CoA reductase on hepatic metabolism of cholesterol. New Engl J Med 1990, 323:224-228.
23. Halpern Z, Dudley MA, Lynn MP, Nader JM, Breuer AC, Holzbach RT: Vesicle aggregation in model systems of supersaturated bile: relation to crystal nucleation and lipid composition of the vesicular phase. J Lipid Res 1986, 27:295-306.
24. Van Erpecum KJ, Van Berge-Henegouwen GP, Stoelwinder B, Schmidt YMG, Willekens FLH: Bile concentration is a key factor for nucleation of cholesterol crystals and cholesterol saturation index in gallbladder bile of gallstone patients. Hepatology 1990, 11:1-6.
25. Carey MC, Cohen DE: Biliary transport of cholesterol in vesicles, micelles and liquid crystals. In Bile Acids and the Liver: with an Update on Gallstone Disease. Edited by G Paumgartner, A Stiehl, W Gerok. Lancaster, PA: MTP Press Ltd; 1987: 287-300.
26. Tazuma S, Holzbach RT: Transport of conjugated bilirubin and other organic anions in bile: relation to biliary lipid structures. Proc Natl Acad Sci USA 1987, 84:2052-2056.
27. Tazuma S, Barnhart RL, Reeve LE, Tokumo H, Holzbach RT: Biliary secretion of organic anions in the dog: association with defined lipid particles. Am J Physiol 1988, 255:G745-G751.